+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

The Exposome in Cancer Disparities. Influence of Environmental and Infectious Factors in LMICs

  • Book

  • June 2026
  • Elsevier Science and Technology
  • ID: 6250724

The Exposome in Cancer Disparities: Influence of Environmental and Infectious Factors in LMICs examines how environmental and infectious factors drive cancer inequities in low- and middle-income countries (LMICs). The book introduces the exposome as a comprehensive framework to understand complex risk factors, such as environmental toxins, climate change, and infectious agents like HPV and HIV. The book combines scientific insights, real-world case studies, and practical strategies from international experts, highlighting region-specific contributors to cancer disparities. Structured into thematic sections, it offers a holistic view of the challenges faced by LMICs and provides actionable, evidence-based solutions tailored to resource-limited settings.

The work emphasizes the importance of multidisciplinary approaches and international collaboration to develop effective prevention and policy strategies. It will benefit researchers, policymakers, and healthcare professionals by deepening understanding of cancer risk factors, fostering global cooperation and guiding targeted interventions to reduce health inequities and improve outcomes worldwide.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

I: Foundations of exposomics and cancer disparities

  1. Introduction: The exposome framework and its relevance to cancer disparities
  2. Environmental exposures and cancer risk: An exposomics perspective in low- and middle-income countries
  3. Infectious agents, HIV, and carcinogenic risks of cancer in low- and middle-income countries
  4. Socioeconomic inequities and the exposome: A double burden in low- and middle-income countries

II: Mechanisms and intersections of the exposome

  1. Neglected tropical diseases, coinfections, and the exposome: The overlapping burden in low- and middle-income countries
  2. Climate change, the exposome, and cancer disparities in low- and middle-income countries
  3. Culture, society, and the exposome: Understanding cancer risk in low- and middle-income countries
  4. Gene-environment interactions: The exposome and cancer susceptibility
  5. The microbiome and the exposome: Implications for cancer risk

III: Exposome-informed strategies for cancer prevention and equity

  1. Cancer prevention in low- and middle-income countries: Targeting environmental and infectious exposures
  2. Strengthening healthcare systems through exposomics
  3. Policy reform and environmental justice: Bridging gaps in cancer prevention

IV: Innovations and global collaboration in exposomics

  1. Emerging technologies in exposomics: Advancing cancer diagnosis and treatment
  2. Artificial intelligence, big data, and the exposome: Transforming cancer risk assessment
  3. Global collaboration in exposomics: A multistakeholder approach to reducing cancer disparities
  4. The future of exposomics: Pathways to address cancer disparities in low- and middle-income countries

Authors

Zodwa Dlamini University of Pretoria, South Africa. Zodwa Dlamini is a Professor of Molecular Oncology and the founding Director and the Executive Head of the Pan African Cancer Research Institute (PACRI) in South Africa. She is the Director of South African Medical Research Council (SAMRC) Precision Oncology Research Unit (PORU). She is the DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP). She is a member of the American Association for Cancer Research (AACR) Advisory Group on Sub-Saharan Africa. She is a member of the AACR Pathology Resources in Africa Advisory Group. Professor Dlamini is a member of the African Organisation for Research and Training in Cancer (AORTIC) Research Committee Scientific Advisory Board. She is an elected member of the Academy of Science of South Africa. Professor Dlamini is an overseas Fellow of the Royal Society of Medicine (London). She is the Associate Editor for Frontiers in Oncology: Cancer Genetics Section